Review ArticleClinical Review

Guidelines for the Management of Cognitive and Behavioral Problems in Dementia

Carl H. Sadowsky and James E. Galvin
The Journal of the American Board of Family Medicine May 2012, 25 (3) 350-366; DOI: https://doi.org/10.3122/jabfm.2012.03.100183

References

  1. 1.↵
    1. Downs M,
    2. Turner S,
    3. Bryans M,
    4. et al
    . Effectiveness of educational interventions in improving detection and management of dementia in primary care: cluster randomised controlled study. BMJ 2006;332:692–6.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. van Hout H,
    2. Vernooij-Dassen M,
    3. Bakker K,
    4. Blom M,
    5. Grol R
    . General practitioners on dementia: tasks, practices and obstacles. Patient Educ Couns 2000;39:219–25.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Knopman D,
    2. Donohue JA,
    3. Gutterman EM
    . Patterns of care in the early stages of Alzheimer's disease: impediments to timely diagnosis. J Am Geriatr Soc 2000;48:300–4.
    OpenUrlPubMedWeb of Science
  4. 4.↵
    1. Bullock R
    . New drugs for Alzheimer's disease and other dementias. Br J Psychiatry 2002;180:135–9.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Woods RT,
    2. Moniz-Cook E,
    3. Iliffe S,
    4. et al
    . Dementia: issues in early recognition and intervention in primary care. J R Soc Med 2003;96:320–4.
    OpenUrlFREE Full Text
  6. 6.↵
    1. Cummings JL,
    2. Frank JC,
    3. Cherry D,
    4. et al
    . Guidelines for managing Alzheimer's disease: part II. Treatment. Am Fam Physician 2002;65:2525–34.
    OpenUrlPubMedWeb of Science
  7. 7.↵
    1. Cummings JL,
    2. Frank JC,
    3. Cherry D,
    4. et al
    . Guidelines for managing Alzheimer's disease: part I. Assessment. Am Fam Physician 2002;65:2263–72.
    OpenUrlPubMedWeb of Science
  8. 8.↵
    1. Boustani M,
    2. Peterson B,
    3. Hanson L,
    4. Harris R,
    5. Lohr KN
    . Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003;138:927–37.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Waldemar G,
    2. Dubois B,
    3. Emre M,
    4. et al
    . Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1–26.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Rosen WG,
    2. Mohs RC,
    3. Davis KL
    . A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356–64.
    OpenUrlPubMedWeb of Science
  11. 11.↵
    1. Birks J
    . Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD005593.
  12. 12.↵
    National Institute of Clinical Excellence. Dementia: supporting people with dementia and their carers in health and social care. 2006. November 2006, amended March 2011. Available from: http://www.nice.org.uk/nicemedia/live/10998/30318/30318.pdf. Accessed 29 March 2012.
  13. 13.↵
    1. Salmon DP,
    2. Thal LJ,
    3. Butters N,
    4. Heindel WC
    . Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology 1990;40:1225–30.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Ballard CG,
    2. O'Brien J,
    3. James I
    . Dementia: management of behavioral and psychological symptoms. Oxford: Oxford University Press; 2001.
  15. 15.↵
    1. Douglas S,
    2. James I,
    3. Ballard C
    . Non-pharmacological interventions in dementia. Adv Psychiatric Treatment 2004;10:171–9.
    OpenUrl
  16. 16.↵
    1. Salzman C,
    2. Jeste DV,
    3. Meyer RE,
    4. et al
    . Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry 2008;69:889–98.
    OpenUrlCrossRefPubMedWeb of Science
  17. 17.↵
    1. Cohen-Mansfield J
    . Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 2001;9:361–81.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Lim WS,
    2. Gammack JK,
    3. Van Niekerk J,
    4. Dangour AD
    . Omega 3 fatty acid for the prevention of dementia. Cochrane Database Syst Rev 2006;(1):CD005379.
  19. 19.↵
    1. Friedland RP
    . Fish consumption and the risk of Alzheimer disease: is it time to make dietary recommendations? Arch Neurol 2003;60:923–4.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    1. Yang F,
    2. Lim GP,
    3. Begum AN,
    4. et al
    . Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005;280:5892–901.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Poncha F
    . Efficacy and safety of curcumin formulation in Alzheimer's disease. ClinicalTrials.gov identifier: NCT01001637. 15 October 2009, updated 23 October 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT01001637?term=NCT01001637&rank=1. Accessed 15 March 2012.
  22. 22.↵
    1. Llewellyn DJ,
    2. Lang IA,
    3. Langa KM,
    4. Melzer D
    . Vitamin D and cognitive impairment in the elderly U.S. population. J Gerontol A Biol Sci Med Sci 66:59–65.
  23. 23.↵
    1. Llewellyn DJ,
    2. Lang IA,
    3. Langa KM,
    4. et al
    . Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med 170:1135–41.
  24. 24.↵
    1. Reger MA,
    2. Henderson ST,
    3. Hale C,
    4. et al
    . Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging 2004;25:311–4.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    Accera. Axona description. Available from: http://www.about-axona.com/wordpress/wp-content/uploads/prescribinginformation.pdf. Accessed 29 March 2012.
  26. 26.↵
    Nutricia. The Science Behind Souvenaid®. Available from: http://souvenaid.nutricia.com/the-science-behind-souvenaid.html. Accessed 29 March 2012.
  27. 27.↵
    1. Scheltens P,
    2. Verhey FRJ,
    3. Olde Rikkert MGM,
    4. Kamphuis PJGH,
    5. Wilkinson D,
    6. Kurz A
    . The efficacy of a medical food (Souvenaid) in Alzheimer's disease: results from the first trial and design of future trials. Alzheimers Dement 2009;5(Suppl):258–9.
    OpenUrl
  28. 28.↵
    1. Farlow MR,
    2. Cummings JL
    . Effective pharmacologic management of Alzheimer's disease. Am J Med 2007;120:388–97.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Geldmacher DS
    . Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care. Prim Care Companion J Clin Psychiatry 2007;9:113–21.
    OpenUrlPubMed
  30. 30.↵
    1. Salloway S,
    2. Correia S
    . Alzheimer disease: time to improve its diagnosis and treatment. Cleve Clin J Med 2009;76:49–58.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Birks J,
    2. Grimley Evans J,
    3. Iakovidou V,
    4. Tsolaki M,
    5. Holt FE
    . Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009;(2):CD001191.
  32. 32.↵
    1. Winblad B,
    2. Grossberg G,
    3. Frolich L,
    4. et al
    . IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007;69:S14–22.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Guerin O,
    2. Andrieu S,
    3. Schneider SM,
    4. et al
    . Different modes of weight loss in Alzheimer disease: a prospective study of 395 patients. Am J Clin Nutr 2005;82:435–41.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Kaduszkiewicz H,
    2. Zimmermann T,
    3. Beck-Bornholdt HP,
    4. van den Bussche H
    . Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005;331:321–7.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Qaseem A,
    2. Snow V,
    3. Cross JT Jr.,
    4. et al
    . Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008;148:370–8.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.↵
    1. Cummings JL
    . Searching for methods to detect, prevent, and treat Alzheimer's disease. Am J Psychiatry 2005;162:645–7.
    OpenUrlPubMed
  37. 37.↵
    1. Farlow M,
    2. Potkin S,
    3. Koumaras B,
    4. Veach J,
    5. Mirski D
    . Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week. Alzheimer disease trial. Arch Neurol 2003;60:843–8.
    OpenUrlCrossRefPubMedWeb of Science
  38. 38.↵
    1. Hashimoto M,
    2. Kazui H,
    3. Matsumoto K,
    4. Nakano Y,
    5. Yasuda M,
    6. Mori E
    . Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005;162:676–82.
    OpenUrlCrossRefPubMedWeb of Science
  39. 39.↵
    1. Raina P,
    2. Santaguida P,
    3. Ismaila A,
    4. et al
    . Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008;148:379–97.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Doraiswamy PM,
    2. Kaiser L,
    3. Bieber F,
    4. Garman RL
    . The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord 2001;15:174–83.
    OpenUrlCrossRefPubMedWeb of Science
  41. 41.↵
    1. Lanctot KL,
    2. Herrmann N,
    3. Yau KK,
    4. et al
    . Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557–64.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Trinh NH,
    2. Hoblyn J,
    3. Mohanty S,
    4. Yaffe K
    . Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003;289:210–6.
    OpenUrlCrossRefPubMedWeb of Science
  43. 43.↵
    1. Doody RS,
    2. Stevens JC,
    3. Beck C,
    4. et al
    . Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154–66.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Feldman H,
    2. Gauthier S,
    3. Hecker J,
    4. et al
    . Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003;51:737–44.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    1. Marin D,
    2. Amaya K,
    3. Casciano R,
    4. et al
    . Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease. Int Psychogeriatr 2003;15:385–98.
    OpenUrlPubMedWeb of Science
  46. 46.↵
    1. Lopez OL,
    2. Becker JT,
    3. Saxton J,
    4. Sweet RA,
    5. Klunk W,
    6. DeKosky ST
    . Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition. J Am Geriatr Soc 2005;53:83–7.
    OpenUrlCrossRefPubMedWeb of Science
  47. 47.↵
    1. Beusterien KM,
    2. Thomas SK,
    3. Gause D,
    4. Kimel M,
    5. Arcona S,
    6. Mirski D
    . Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs 2004;18:1143–8.
    OpenUrlCrossRefPubMedWeb of Science
  48. 48.↵
    1. Peskind ER,
    2. Potkin SG,
    3. Pomara N,
    4. et al
    . Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006;14:704–15.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    1. Rogawski MA,
    2. Wenk GL
    . The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev 2003;9:275–308.
    OpenUrlPubMedWeb of Science
  50. 50.↵
    1. Reisberg B,
    2. Doody R,
    3. Stoffler A,
    4. Schmitt F,
    5. Ferris S,
    6. Mobius HJ
    . Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333–41.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    1. Farlow MR,
    2. Salloway S,
    3. Tariot PN,
    4. et al
    . Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther;32:1234–51.
  52. 52.↵
    1. Tariot PN,
    2. Farlow MR,
    3. Grossberg GT,
    4. Graham SM,
    5. McDonald S,
    6. Gergel I
    . Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317–24.
    OpenUrlCrossRefPubMedWeb of Science
  53. 53.↵
    1. Weycker D,
    2. Taneja C,
    3. Edelsberg J,
    4. et al
    . Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil. Curr Med Res Opin 2007;23:1187–97.
    OpenUrlPubMed
  54. 54.↵
    1. Olin JT,
    2. Bhatnagar V,
    3. Reyes P,
    4. Koumaras B,
    5. Meng X,
    6. Brannan S
    . Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (study ENA713B US32). Int J Geriatr Psychiatry 25:419–26.
  55. 55.↵
    1. Olazaran J,
    2. Muniz R,
    3. Reisberg B,
    4. et al
    . Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease. Neurology 2004;63:2348–53.
    OpenUrlAbstract/FREE Full Text
  56. 56.↵
    1. Fillit HM,
    2. Doody RS,
    3. Binaso K,
    4. et al
    . Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother 2006;4(Suppl 1):S9–S24; quiz S5–S8.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. deSouza L,
    2. Sarazin M,
    3. Goetz C,
    4. Dubois B
    . Clinical investigations in primary care. Front Neurol Neurosci 2009;24:1–11.
    OpenUrlPubMed
  58. 58.↵
    1. Finkel SI,
    2. Costa e Silva J,
    3. Cohen G,
    4. Miller S,
    5. Sartorius N
    . Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 1996;3(8 Suppl):497–500.
    OpenUrl
  59. 59.↵
    1. Christensen DD,
    2. Lin P
    . Practical treatment strategies for patients with Alzheimer's disease. J Fam Pract 2007;56:S17–23.
    OpenUrlPubMed
  60. 60.↵
    1. Schultz R,
    2. Williamson GH
    . A 2-year longitudinal study of depression among Alzheimer's caregivers. Psychol Aging 1991;6:569–78.
    OpenUrlCrossRefPubMedWeb of Science
  61. 61.↵
    1. Teri L,
    2. Logsdon RG,
    3. McCurry SM
    . Nonpharmacologic treatment of behavioral disturbance in dementia. Med Clin North Am 2002;86:641–56, viii.
    OpenUrlCrossRefPubMedWeb of Science
  62. 62.↵
    1. Logsdon RG,
    2. McCurry SM,
    3. Teri L
    . Evidence-based psychological treatments for disruptive behaviors in individuals with dementia. Psychol Aging 2007;22:28–36.
    OpenUrlCrossRefPubMedWeb of Science
  63. 63.↵
    1. Emerson E
    . Working with people with challenging behavior. Chichester: John Wiley and Sons; 1998.
  64. 64.↵
    1. Ballard C,
    2. O'Brien J
    . Treating behavioural and psychological signs in Alzheimer's disease. BMJ 1999;319:138–9.
    OpenUrlFREE Full Text
  65. 65.↵
    1. Haupt M,
    2. Karger A,
    3. Janner M
    . Improvement of agitation and anxiety in demented patients after psychoeducative group intervention with their caregivers. Int J Geriatr Psychiatry 2000;15:1125–9.
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Hepburn KW,
    2. Lewis M,
    3. Sherman CW,
    4. Tornatore J
    . The savvy caregiver program: developing and testing a transportable dementia family caregiver training program. Gerontologist 2003;43:908–15.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Kovach CR,
    2. Taneli Y,
    3. Dohearty P,
    4. Schlidt AM,
    5. Cashin S,
    6. Silva-Smith AL
    . Effect of the BACE intervention on agitation of people with dementia. Gerontologist 2004;44:797–806.
    OpenUrlAbstract/FREE Full Text
  68. 68.↵
    1. Teri L,
    2. McCurry SM,
    3. Logsdon R,
    4. Gibbons LE
    . Training community consultants to help family members improve dementia care: a randomized controlled trial. Gerontologist 2005;45:802–11.
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    1. Ostwald SK,
    2. Hepburn KW,
    3. Caron W,
    4. Burns T,
    5. Mantell R
    . Reducing caregiver burden: a randomized psychoeducational intervention for caregivers of persons with dementia. Gerontologist 1999;39:299–309.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Herrmann N,
    2. Gauthier S
    . Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. CMAJ 2008;179:1279–87.
    OpenUrlAbstract/FREE Full Text
  71. 71.↵
    1. Teri L,
    2. Gallagher-Thompson D
    . Cognitive-behavioral interventions for treatment of depression in Alzheimer's patients. Gerontologist 1991;31:413–6.
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    1. Kipling T,
    2. Bailey M,
    3. Charlesworth G
    . The feasibility of a cognitive behavioural therapy group for men with a mild/moderate cognitive impairment. Behav Cogn Psychother 1999;27:189–93.
    OpenUrl
  73. 73.↵
    1. Schneider LS,
    2. Dagerman KS,
    3. Insel P
    . Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934–43.
    OpenUrlCrossRefPubMedWeb of Science
  74. 74.↵
    1. McShane R,
    2. Keene J,
    3. Gedling K,
    4. Fairburn C,
    5. Jacoby R,
    6. Hope T
    . Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up. BMJ 1997;314:266–70.
    OpenUrlAbstract/FREE Full Text
  75. 75.↵
    1. Schneider LS,
    2. Tariot PN,
    3. Dagerman KS,
    4. et al
    . Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525–38.
    OpenUrlCrossRefPubMedWeb of Science
  76. 76.↵
    1. Pollock BG,
    2. Mulsant BH,
    3. Rosen J,
    4. et al
    . Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002;159:460–5.
    OpenUrlCrossRefPubMedWeb of Science
  77. 77.↵
    1. Pollock BG,
    2. Mulsant BH,
    3. Rosen J,
    4. et al
    . A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007;15:942–52.
    OpenUrlCrossRefPubMedWeb of Science
  78. 78.↵
    1. Landes AM,
    2. Sperry SD,
    3. Strauss ME,
    4. Geldmacher DS
    . Apathy in Alzheimer's disease. J Am Geriatr Soc 2001;49:1700–7.
    OpenUrlCrossRefPubMedWeb of Science
  79. 79.↵
    1. Boyle PA,
    2. Malloy PF
    . Treating apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 2004;17:91–9.
    OpenUrlPubMed
  80. 80.↵
    1. Dolder CR,
    2. Davis LN,
    3. McKinsey J
    . Use of psychostimulants in patients with dementia. Ann Pharmacother 2010;44:1624–32.
    OpenUrlCrossRefPubMedWeb of Science
  81. 81.↵
    1. Lyketsos CG,
    2. Sheppard JM,
    3. Steele CD,
    4. et al
    . Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry 2000;157:1686–0.
    OpenUrlCrossRefPubMedWeb of Science
  82. 82.↵
    1. Mittelman MS,
    2. Ferris SH,
    3. Shulman E,
    4. et al
    . A comprehensive support program: effect on depression in spouse-caregivers of AD patients. Gerontologist 1995;35:792–802.
    OpenUrlAbstract/FREE Full Text
  83. 83.↵
    1. Mittelman MS,
    2. Ferris SH,
    3. Shulman E,
    4. Steinberg G,
    5. Levin B
    . A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA 1996;276:1725–31.
    OpenUrlCrossRefPubMedWeb of Science
  84. 84.↵
    1. Mittelman MS,
    2. Haley WE,
    3. Clay OJ,
    4. Roth DL
    . Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease. Neurology 2006;67:1592–9.
    OpenUrlAbstract/FREE Full Text
  85. 85.↵
    1. Dubois B,
    2. Picard G,
    3. Sarazin M
    . Early detection of Alzheimer's disease: new diagnostic criteria. Dialogues Clin Neurosci 2009;11:135–9.
    OpenUrlPubMed
  86. 86.↵
    1. Bolognesi ML,
    2. Rosini M,
    3. Andrisano V,
    4. et al
    . MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond. Curr Pharm Des 2009;15:601–13.
    OpenUrlCrossRefPubMedWeb of Science
  87. 87.↵
    1. Duara R,
    2. Barker W,
    3. Loewenstein D,
    4. Bain L
    . The basis for disease-modifying treatments for Alzheimer's disease: the Sixth Annual Mild Cognitive Impairment Symposium. Alzheimers Dement 2009;5:66–74.
    OpenUrlCrossRefPubMed
  88. 88.↵
    1. Bates KA,
    2. Verdile G,
    3. Li QX,
    4. et al
    . Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 2009;14:469–86.
    OpenUrlCrossRefPubMed
  89. 89.↵
    1. Tarawneh R,
    2. Holtzman DM
    . Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets 2009;8:144–59.
    OpenUrlCrossRefPubMedWeb of Science
  90. 90.↵
    1. Caccamo A,
    2. Fisher A,
    3. LaFerla FM
    . M1 agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr Alzheimer Res 2009;6:112–7.
    OpenUrlCrossRefPubMedWeb of Science
  91. 91.↵
    1. Conn PJ,
    2. Jones CK,
    3. Lindsley CW
    . Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharmacol Sci 2009;30:148–55.
    OpenUrlCrossRefPubMedWeb of Science
  92. 92.↵
    1. Lermontova NN,
    2. Redkozubov AE,
    3. Shevtsova EF,
    4. Serkova TP,
    5. Kireeva EG,
    6. Bachurin SO
    . Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull Exp Biol Med 2001;132:1079–83.
    OpenUrlPubMed
  93. 93.↵
    1. Bachurin SO,
    2. Shevtsova EP,
    3. Kireeva EG,
    4. Oxenkrug GF,
    5. Sablin SO
    . Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci. 2003;993:334–44.
    OpenUrlPubMedWeb of Science
  94. 94.↵
    1. Doody RS,
    2. Gavrilova SI,
    3. Sano M,
    4. et al
    . Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008;372:207–15.
    OpenUrlCrossRefPubMedWeb of Science
  95. 95.↵
    1. Leifer BP
    . Alzheimer's disease: seeing the signs early. J Am Acad Nurse Pract 2009;21:588–95.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section